2450 HOLCOMBE BLVD, HOUSTON, TX
2026 Annual Meeting Results; Directors Elected and Compensation Approved
Investor Presentation
Material disclosure
Announces 1-for-12 Reverse Stock Split
Stockholders Approve 2026 Equity Incentive Plan at Special Meeting
Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Salarius Pharmaceuticals Re-Elects Directors at 2025 Annual Meeting
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Q2
Q1
Amended Annual Report
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
RW
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload